Q2 in brief: better overall Our impression is that Svedbergs Group's Q2 report is better than Factse...
Redeye provides a short comment on the Q2 2025 report from Sdiptech, which came in below our estimat...
Redeye comments on Truecaller’s Q2 2025 report, which was somewhat softer than expected.
Redeye updates on Evolution post Q2-results which were largely in line with our forecasts.
Redeye comments on the negative topline data in the TRIFOUR study and provides a new base case.
Atria's Q2 EBIT of EUR 17.6m came in above LSEG Data & Analytics consensus expectations despite temp...
Net sales and EBIT were slightly below consensus (LSEG Data & Analytics) in Q2.
Redeye retains its positive view of Vertiseit following the Q2 report.
Redeye comments on CombinedX’s Q2 report, showing negative growth and lower margins than expected.
Q2 expectations Studsvik will report its Q2 on 22 July, and we forecast sales of SEK 246m, +5% y-o-y...
Exitmarknaderna har vaknat till liv igen och VEF har använt del av likviden från årets tre exits til...
Atria reported Q2 adjusted EBIT of EUR 17.6m, 7% above LSEG Data & Analytics consensus.
Vitrolife faces a tough 2025, and we expect this to continue during H2 2025, at best, at a fading ra...
Redeye comments on OncoZenge’s recent amendment to its licensing agreement with Molteni Farmaceutici...
Redeye shares its initial thoughts on CTEK’s Q2 report, which we think came in slightly softer than ...
